HealthQuill Clinical trials
The USFDA has approved GSK Plc’s oral therapy to treat anaemia in patients with myelofibrosis, a type of bone cancer.
Health

Engineered marrow cells cut fractures in osteoporosis patients in tiny trial

HQ Team September 24, 2026: Osteoporosis, a disease that thins bones and makes patients vulnerable to fractures at the slightest falls. This progressive.

Read More
The European Commission has approved AbbVie Inc.’s drug for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs.
Drugs Health Pharma

EC approves AbbVie Inc.s drug for a type of juvenile idiopathic arthritis

HQ Team September 22, 2026: The European Commission has approved AbbVie Inc.’s drug for the treatment of active polyarticular juvenile idiopathic arthritis in.

Read More
American pharmaceutical company Johnson & Johnson’s investigational drug met its main goal during end-stage trials for the treatment of manic episodes in adults with bipolar I disorder, according to the company.
Drugs Pharma Research

J&J’s test drug for manic episodes in bipolar disorder meets main goal

HQ Team September 22, 2026: American pharmaceutical company Johnson & Johnson’s investigational drug met its main goal during end-stage trials for the treatment.

Read More
Danish drugmaker Novo Nordisk’s investigational drug, CagriSema, has achieved an estimated average weight loss of 12.4% in diabetic patients during an end-stage trial, better than rival Eli Lilly’s drug.
Health Pharma Research

Novo Nordisk’s test drug outperforms rival Lilly’s in diabetic patients

HQ Team September 21, 2026: Danish drugmaker Novo Nordisk’s investigational drug, CagriSema, has achieved an estimated average weight loss of 12.4% in diabetic.

Read More
Australia's Telix Pharmaceuticals will buy ITM Isotope Technologies Munich SE for an upfront payment of $1.65 billion on a cash- and debt-free basis to pocket the Germany-based company’s therapeutic radioisotopic solutions.
Drugs Health Pharma

Australia’s Telix to buy ITM Isotope Technologies for $1.65 billion

HQ Team September 21, 2026: Australia’s Telix Pharmaceuticals will buy ITM Isotope Technologies Munich SE for an upfront payment of $1.65 billion on.

Read More
AbbVie Inc.’s experimental drug has reduced the number of migraine days during the menstrual period, meeting a key goal in late-stage trials, the company announced.
Drugs Medical Pharma

AbbVie’s late-stage experimental drug reduces menstrual migraine days

HQ Team September 11, 2026: AbbVie Inc.’s experimental drug has reduced the number of migraine days during the menstrual period, meeting a key.

Read More
Novartis AG’s experimental drug to treat a neuromuscular disease failed to meet its target, the company announced.
Drugs Medical Pharma

Novartis’s neuromuscular experimental drug fails to meet targets

HQ Team September 9, 2026: Novartis AG’s experimental drug to treat a neuromuscular disease failed to meet its target, the company announced. The.

Read More
Novartis AG will buy a US-based private biotech company, Excellergy, Inc, for $2 billion to expand its allergy portfolio.
Drugs Health Pharma

Novartis AG to acquire Exellergy for $2 billion, expand allergy portfolio

Novartis AG will buy a US-based private biotech company, Excellergy, Inc, for $2 billion to expand its allergy portfolio.

Read More
Pfizer Inc. and France-based Valneva SE's investigational vaccine has shown 70% efficacy in preventing Lyme disease in individuals aged five and above.
Drugs Medical Pharma

Pfizer, Valneva’s experimental Lyme disease vaccine shows 70% efficacy

HQ Team March 25, 2026: Pfizer Inc. and France-based Valneva SE‘s investigational vaccine has shown 70% efficacy in preventing Lyme disease in individuals.

Read More
Gilead Sciences, Inc., will acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases, for $2 billion, according to a statement. 
Drugs Medical Pharma

Gilead Sciences to acquire US-based Ouro Medicines for up to $2 billion 

Gilead Sciences, Inc., will acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases, for.

Read More